Cargando…

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications

Multiple myeloma (MM) is characterized by multiple relapse and, despite the introduction of novel therapies, the disease becomes ultimately drug-resistant. The tumor microenvironment (TME) within the bone marrow niche includes dendritic cells, T-cytotoxic, T-helper, reactive B-lymphoid cells and mac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cencini, Emanuele, Sicuranza, Anna, Ciofini, Sara, Fabbri, Alberto, Bocchia, Monica, Gozzetti, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378698/ https://www.ncbi.nlm.nih.gov/pubmed/37504315 http://dx.doi.org/10.3390/curroncol30070455

Ejemplares similares

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI
por: Santoni, Adele, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
por: Cencini, Emanuele, et al.
Publicado: (2021)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
por: Gozzetti, Alessandro, et al.
Publicado: (2012)

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
por: Del Giudice, Maria Livia, et al.
Publicado: (2021)

Primary CNS lymphoma: latest updates and a 10-year monocenter experience
por: Cencini, Emanuele, et al.
Publicado: (2018)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
por: Attucci, I., et al.
Publicado: (2023)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study
por: Del Giudice, Maria Livia, et al.
Publicado: (2022)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
por: Gandolfo, Claudia, et al.
Publicado: (2022)

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
por: Sicuranza, Anna, et al.
Publicado: (2022)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature
por: Bacchiarri, Francesca, et al.
Publicado: (2022)

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients
por: Bocchia, Monica, et al.
Publicado: (2016)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Flow Cytometry Assessment of CD26(+) Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
por: Raspadori, Donatella, et al.
Publicado: (2019)

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022)

Characteristics of Primary Cutaneous Lymphoma in Italy: A Tertiary Care, Single-Center Study
por: D’Onghia, Martina, et al.
Publicado: (2023)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications
por: Huang, He, et al.
Publicado: (2022)

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
por: Ippoliti, Micaela, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vg9u4otfkth461ampocv3fbhej